Holen Sie sich die Stockscreener-App
0.9039
10.07%
0.0827
Handel nachbörslich:
.94
0.0361
+3.99%
Schlusskurs vom Vortag:
$0.8212
Offen:
$0.809
24-Stunden-Volumen:
647.02K
Relative Volume:
0.95
Marktkapitalisierung:
$52.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-71.17M
KGV:
-0.6503
EPS:
-1.39
Netto-Cashflow:
$-70.97M
1W Leistung:
-0.67%
1M Leistung:
-21.40%
6M Leistung:
-82.68%
1J Leistung:
-85.90%
1-Tages-Spanne:
$0.721
$0.9534
1-Wochen-Bereich:
$0.721
$0.9534
52-Wochen-Spanne:
$0.721
$7.01
Inozyme Pharma Inc Stock (INZY) Company Profile
Firmenname
Inozyme Pharma Inc
Sektor
Branche
Telefon
857-330-4340
Adresse
321 SUMMER STREET, BOSTON
Vergleichen Sie INZY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
0.9039 | 52.75M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Raymond James | Outperform |
| 2024-09-12 | Eingeleitet | Stifel | Buy |
| 2024-08-13 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-26 | Eingeleitet | Jefferies | Hold |
| 2022-02-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-29 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | BofA Securities | Buy |
| 2020-08-18 | Eingeleitet | Cowen | Outperform |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten
Rare Disease Innovator Inozyme Pharma Reveals Latest Progress at Elite Healthcare Conference - Stock Titan
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline By Investing.com - Investing.com South Africa
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline - Investing.com Australia
FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst - Defense World
Raymond James Issues Pessimistic Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush - Defense World
Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World
Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World
Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia
Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com
Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com
H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on Inozyme stock with $16 target - Investing.com
Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks
Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com
Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks
Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq
Inozyme Pharma, Inc. SEC 10-K Report - TradingView
Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization ... - Bluefield Daily Telegraph
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - The Manila Times
Inozyme Pharma Reports Full Year 2024 Financial Results and - GlobeNewswire
Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday - Defense World
Inozyme Pharma Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $18.33 Consensus PT from Analysts - Armenian Reporter
INZY stock touches 52-week low at $1.14 amid market challenges - Investing.com
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of “Buy” by Brokerages - Defense World
Inozyme Pharma stock hits 52-week low at $1.23 amid challenges - Investing.com Canada
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Can Inozyme's Rare Disease Pipeline Transform Bone Health Treatment? CEO Presents Key Data - StockTitan
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - The Manila Times
Inozyme Pharma to Present Recently Announced Interim Data - GlobeNewswire
Can This Rare Disease Treatment Transform Young Lives? New ENPP1 Therapy Data Emerges - StockTitan
Inozyme Pharma stock hits 52-week low at $1.32 amid market challenges - MSN
abrdn plc Makes New $472,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Stock Falling -48.58% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Finanzdaten der Inozyme Pharma Inc-Aktie (INZY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):